Prurigo Nodularis: Recognizing, Diagnosing and Treating a Rare but Debilitating Disease

Access Activity

Overview / Abstract:

Prurigo Nodularis is a rare, chronic skin disorder that causes substantial patient burden, but is often overlooked or misdiagnosed and, until recently, had no medications approved by the US Food and Drug Administration. The interprofessional faculty share their real-world perspectives on the diagnosis and treatment of patients with prurigo nodularis to reduce patient burden of disease and improve health outcomes. Highlighting pathophysiologic mechanisms, the faculty discuss the evolving pharmacologic treatment of patients with prurigo nodularis that now includes dupilumab; they also review safety and efficacy data for medications in late-phase clinical investigation. Case studies are discussed to facilitate integration of key concepts into clinical practice.


Aug 31, 2024


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME



Credits / Hours




Presenters / Authors / Faculty

Jonathan Silverberg, MD, PhD, MPH
Lindsay C. Strowd, MD
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Leigh Ann Pansch, MSN, FNP-BC, DCNP
Najat M. Watch, PA-C

Sponsors / Supporters / Grant Providers

This activity is supported by educational grants from Galderma, and Sanofi and Regeneron Pharmaceuticals.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Diagnosis, Disease burden, Validated measures, Pathophysiologic targets, Evidence-based guidelines, Current treatment, Novel/Emerging treatment Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map